Pharmacells Ltd is delighted to announce the launch of Oristem®; its new stem cell banking service that allows adults of any age to store these vital cells ready to treat diseases that they may get later in life.
Until now, it has only been possible to store cells using invasive, costly techniques – designed to access cell types that have already “chosen” pathways within the body. The cell type stored by Pharmacells is significantly less mature, which in scientific terms means that they have much more potential for use within personalised treatments, therapies or pharmaceuticals. Unlike all other methods, the Oristem® product allows the client to choose when and where their blood is taken. They can then relax in the knowledge that their stem cells have been isolated and stored when they are young and healthy, ready to be returned to them at a time, should it arrive, when they need the cells again to treat a serious illness. Since stem cell efficacy drops as people age, storing cells in this manner provides an insurance policy against ageing and maximises the chance of recovering from diseases which may currently be considered incurable.
Stem cells are the building blocks of life and are essential for repair of damaged areas of the body. Already stem cells are used in several routine treatments for a wide variety of medical concerns including leukaemia, lymphoma, blood disorders and eye cornea damage. Every year billions are spent globally to push forward this amazing new area of science. Research into many health concerns including Alzheimer’s, Parkinson’s, Multiple Sclerosis, Diabetes and Stroke heralds the promise of a new dawn within Medical Science.
Athol Haas, CEO of Pharmacells, said "We have worked extremely hard over the last few years to bring this amazing new breakthrough technology to the market. We’re proud to be able to use our patented technology to help ensure the future health of our clients. Stem cells are at the forefront of a new wave of medical technologies and our Oristem® product offers, for the first time, a cost effective opportunity for anyone to improve their future health and that of their families"
To deliver Oristem®, Pharmacells has partnered with two leading companies in their field, Altrika Ltd (part of Ilika PLC) to process the blood samples and extract the cells, and Vindon Healthcare PLC to provide long term storage. All parties have been inspected and licensed by the UK Human Tissue Authority (HTA), guaranteeing that they operate to the highest standards possible. Together, they have designed unique, temperature controlled collection kits that allow samples to be safely collected almost anywhere in the world and dispatched to Altrika Ltd for processing.
With stem cell research developing quickly and the number of new treatments and therapies expected to rise considerably over the coming years, having quick access to your own healthy cells is a wise health choice. After all, none of us is getting any younger!
NovaBiotics Wins Investment of the Year Award | 5 Feb 2016
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus | 12 Aug 2015
Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium | 12 Jun 2015
Launch of the BEAM Alliance | 9 Jun 2015
NovaBiotics Quoted in "What Investment" on 11 February | 11 Feb 2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management | 19 Jan 2015
NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014 | 7 Oct 2014
Showcases increasing investor interest in the global stem cell sector | 22 Sep 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® | 16 Sep 2014
Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London | 18 August 2014
Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group | 25 July 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year | 27 June 2014
NovaBiotics Initiates Phase IIa Clinical Study for Lynovex in Cystic Fibrosis | 25 June 2014
NovaBiotics' Dr Deborah O'Neil Named EY Scotland Entrepreneur of 2014 | 20 June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis | 17 December 2013
Pharmacells to expand following funding boost | 24 September 2013
NovaBiotics Enters into Agreement with Taro | 28 August 2013
First patient dosed at Aberdeen Royal Infirmary in major international study | 29 August 2012
Pharmacells in talks to extend reach overseas | 24 January 2012
New hope in cystic fibrosis fight as Scots patients first to test drug | 2 January 2012
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status | 19 December 2011
Pharmacells stores stem cells for teenager paralysed in car crash | 20 October 2011
NovaBiotics Ltd - Presentation at BIO International 2011, Washington DC | 24 June 2011
Launch of Oristem® | 04 June 2011
GBP in Nexxus newsletter, Spring 2011 | 22 March 2011
Patents granted in key territories as Novexatin® moves closer to further clinical development and commercialisation | 21 February 2011
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin®, Nova... | 5 July 2010
Successful Completion of Phase IIa clinical trial for Novexatin®, IND filing planned for Phase IIb... | 1 May 2010
NovaBiotics Wins Investment of the Year Award
5th February 2015
Launch of the BEAM Alliance
9th June 2015
NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015
Showcases increasing investor interest in the global stem cell sector
22nd September 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year
27th June 2014